Board of Directors

Adam Schechter became chief executive officer of Labcorp (NYSE: LH) in November 2019 and chairman in May 2020. Previously, Schechter was named lead independent director in January 2019 after serving on the board since 2013.

Under Schechter’s leadership, Labcorp, a leading global life sciences company with more than 80,000 employees, harnesses science, innovation and technology to improve health and improve lives. Through its strong diagnostics and drug development capabilities, vast health data and insights, and extensive global laboratory network, the company advances healthcare across all major clinical and therapeutic areas, including oncology, Alzheimer’s, autoimmune and liver diseases, and more.

Labcorp is helping customers bring innovative, life-changing treatments and vaccines to market by leveraging its combined expertise in drug development and diagnostics. With these capabilities, Schechter, with his colleagues at Labcorp, created a model for addressing emerging health crises with their response to the COVID-19 pandemic and the Monkeypox virus.

Schechter joined Labcorp after a long and distinguished career at Merck, where he served as executive vice president and president of global human health and was a member of the executive committee. At Merck, among other accomplishments, Schechter focused on ensuring that Merck’s medicines and vaccines were available to people around the world, led a large global organization across the spectrum of commercial operations, transformed Merck’s commercial model, and led the integration of Merck and Schering-Plough.

He is the vice chair of the Board of Directors for the American Clinical Laboratory Association (ACLA), a board member for Water.org, and serves as an independent director on the board of DaVita, Inc. Schechter is chair of the Corporate Advisory Council for the National Alliance for Hispanic Health, a longtime leader and advocate on Hispanic issues and an Executive Advisor to its Healthy Americas Foundation.

Schechter holds a Bachelor of Arts in Biology from La Salle University and was awarded an honorary Doctor of Humane Letters degree from the university in 2021.

Kerrii B. Anderson has served as a director of the Company since May 17, 2006. Ms. Anderson is the former Chief Executive Officer, President and Chief Financial Officer of Wendy’s International. Prior to joining Wendy’s in 2000, she was senior vice president and chief financial officer for 14 years for M/I Schottenstein Homes, Inc., a NYSE company that builds single-family homes.

Ms. Anderson has served as a director of Abercrombie & Fitch Co. since February 2018, The Sherwin-Williams Company since April 2019, and Worthington Industries, Inc. since September 2010. She was previously a director of the board of Chiquita Brands International from 2009 to 2012, and was chairwoman of the board from 2012 until the company’s acquisition in 2015. She was also a member of the board of P.F. Chang’s China Bistro from 2009 to 2012. Ms. Anderson also serves on the boards of the following non-profit entities: The Columbus Foundation and Elon University Board of Trustees.

Ms. Anderson has a strong record of leadership in operations, strategy, finance and talent management as a result of her experience at Wendy’s. Ms. Anderson also has significant expertise in the areas of accounting and financial reporting, corporate finance, corporate governance, and executive compensation through her service on other large public company boards. The breadth of experience enables Ms. Anderson to advise our Board on a variety of matters related to global operations and business strategy.

Jeffrey A. Davis has served as a director of the Company since December 1, 2019. Mr. Davis currently serves as the Chief Financial Officer of Dollar Tree, Inc., a leading operator of discount variety stores, a role he has held since October 2022. Prior to his time at Dollar Tree, Inc., Mr. Davis served as Chief Financial Officer of Qurate Retail Group, a leading retailer and media conglomerate comprised of eight retail brands including QVC, HSN and Zulily, from October 2018 through August 2022. Prior to Qurate Retail Group, Mr. Davis served as Chief Financial Officer of J. C. Penney Company Inc., a retail company, from July 2017 until September 2018. Prior to joining J. C. Penney, Mr. Davis served as Chief Financial Officer of Darden Restaurants Inc., a restaurant operator, from July 2015 until March 2016 and Chief Financial Officer of the Walmart U.S. segment of Walmart Inc. from January 2014 to May 2015, and in various other positions of increasing responsibility at Walmart U.S. from 2006 to 2013. Mr. Davis’ experience also includes nine years in senior executive roles at Lakeland Tours LLC and McKesson Corporation. Mr. Davis is a Certified Public Accountant and holds a bachelor’s degree in accounting from the Pennsylvania State University and a master’s degree in business administration from the Joseph M. Katz Graduate School of Business at the University of Pittsburgh.

D. Gary Gilliland has served as a director of the Company since April 1, 2014. Dr. Gilliland has served as President and Director Emeritus of the Fred Hutchinson Cancer Research Center, a research organization, in Seattle, WA since January 31, 2020. From January 2, 2015 to January 30, 2020, Dr. Gilliland previously served as President and Director of the Fred Hutchinson Cancer Research Center. Prior to that, he was the inaugural Vice Dean and Vice President for Precision Medicine at the University of Pennsylvania Perelman School of Medicine from October 2013 to January 2015, where he was responsible for synthesizing research and clinical-care initiatives across all medical disciplines including cancer, heart and vascular medicine, neurosciences, genetics, and pathology, to create a national model for the delivery of precise, personalized medicine. From 2009 until he joined Penn Medicine in 2013, Dr. Gilliland was Senior Vice President of Merck Research Laboratories and Oncology Franchise Head. At Merck, Dr. Gilliland oversaw first-in-human studies, proof-of-concept trials, and Phase II/III registration trials that included the development of pembrolizumab (anti-PD1) for treatment of cancer, and managed all preclinical and clinical oncology-licensing activities. Prior to joining Merck, Dr. Gilliland was a member of the faculty at Harvard Medical School for nearly 20 years, where he served as Professor of Medicine and a Professor of Stem Cell and Regenerative Biology. He was also an Investigator of the Howard Hughes Medical Institute from 1996 to 2009, Director of the Leukemia Program at the Dana-Farber/Harvard Cancer Center from 2002 to 2009, and Director of the Cancer Stem Cell Program of the Harvard Stem Cell Institute from 2004 to 2009. Dr. Gilliland has a Ph.D. in Microbiology from UCLA and an M.D. from UCSF. He is board-certified in Internal Medicine and had his Fellowship training in Hematology and Oncology, each at Harvard Medical School. He is a Fellow of the American Association for Cancer Research (AACR), and is an elected member of the American Society of Clinical Investigation (ASCI), the Association of American Physicians (AAP), the American Academy of Arts of Sciences (AAAS) and the National Academy of Medicine (NAM).

Kirsten M. Kliphouse has served as a director of the Company since October 12, 2022. Ms. Kliphouse previously served as the President of Google Cloud Americas, a position she held from March 2022 to June 2023, where she was responsible for leading and growing the sales, go-to-market, customer engagement, channel, and services organizations. At Google Cloud, she also served as the Global Chair of the Aspiring Leadership Academy and Women@Google Cloud. Prior to her position as President, Ms. Kliphouse served as President of the North American division of Google Cloud from June 2019 to March 2022. Ms. Kliphouse has served as a director of Dun & Bradstreet Holdings, Inc. since July 2023 and has also served as a director of Global Payments, Inc. since October 2023.

Prior to Google Cloud, Ms. Kliphouse was Senior Vice President at Red Hat, Inc., a subsidiary of International Business Machines Corporation, Chief Executive Officer of Yardarm Technologies, a hardware and software solutions company, and founder and Chief Executive Officer of Scaling Ventures, a technology investment and advisory firm. Prior to her position at Yardarm, Ms. Kliphouse spent more than 25 years at Microsoft, Inc., where she was part of the executive leadership team and held numerous executive positions in Enterprise Sales, Original Equipment Manufacturers (OEM), Partner and Channels, and as Corporate Vice President of Customer Support, Success and Professional Services, during which she led more than 10,000-employees globally. Ms. Kliphouse is a recipient of the Founders Award for her superior leadership and contributions to the business. Ms. Kliphouse holds a degree in Computer Information Sciences and Business from Muhlenberg College.

Garheng Kong has served as a director of the Company since December 1, 2013 and Lead Independent Director since June 2023. Dr. Kong also serves as the Chair of the Nominating and Corporate Governance Committee for the Company. Dr. Kong is the managing partner of HealthQuest Capital, a healthcare-focused investment firm, a role he has held since he founded HealthQuest Capital in 2012. He was previously a general partner at Sofinnova Capital, a position he held from 2010 to 2013. Before joining Sofinnova, Dr. Kong was a general partner from 2000 to 2010 at Intersouth Partners, a venture capital firm where he was a founding investor or board member for various life science ventures, several of which were acquired by large pharmaceutical companies. Prior to his investing career, Dr. Kong was employed by GlaxoSmithKline, McKinsey & Company, and TherOx. Dr. Kong has served on the board of directors of Venus Concept Inc., a medical technology company, since June 2017, when HealthQuest made an investment in Venus Concept and also currently serves on the board of directors of Xeris Pharmaceuticals, a biopharma company (formerly Strongbridge Biopharma plc, where Dr. Kong served on the board of directors since 2015). Dr. Kong previously served on the board of directors of Alimera Sciences, Inc., a pharmaceutical company that specializes in the commercialization and development of ophthalmic pharmaceuticals, from October 2012 to May 2023 and of Histogenics Corporation, a public biotechnology company, from July 2012 until February 2019, each of which he joined in connection with an investment by Sofinnova, and Avedro, Inc., a commercial-stage ophthalmic medical technology company, from April 2017 until November 2019. Dr. Kong also previously served on the Board of Melinta Therapeutics, a pharmaceutical company formerly known as Cempra Pharmaceuticals, from September 2006 until June 2019. Dr. Kong also sits on the boards of Duke University Medical Center, Be The Match, Dell Children’s Foundation, UT President’s Commercial Advisory Board, and the Austin Healthcare Council. Dr. Kong received undergraduate degrees in both Chemical Engineering and Biological Sciences from Stanford, and earned an M.D., Ph.D. and MBA from Duke University.

Peter M. Neupert has served as a director of the Company since January 1, 2013. Mr. Neupert was an Operating Partner at Health Evolution Partners, a health only, middle market private equity firm, from January 2012 until June 2015. Prior to that, Mr. Neupert served as Corporate Vice President of the Microsoft Health Solutions Group from its formation in 2005 to January 2012. Mr. Neupert served on the President’s Information Technology Advisory Committee (PITAC), co-chairing the Health Information Technology Subcommittee and helping to drive the “Revolutionizing Health Care Through Information Technology” report, published in June 2004. Mr. Neupert served as the founding President and Chief Executive Officer of drugstore.com from 1998 to 2001 and as Chairman of the board of directors through September 2004. Mr. Neupert has served as a director of Fortrea Holdings, Inc. since it became publicly traded in June 2023. Mr. Neupert has served as a director of Adaptive Biotechnologies Corporation since December 2013 and currently serves as the Lead Independent Director. He served on the Board of Directors of Quality Systems, Inc., now known as NextGen Healthcare, Inc., from August 2013 to January 2014. He previously served as a trustee for the Fred Hutchinson Cancer Research Center and was an active member of the Institute of Medicine’s Roundtable on Value & Science-Driven Healthcare from 2007 to 2011. Mr. Neupert brings to the Board experience as a recognized expert in health information technology and perspective on how to grow shareholder value leveraging business strategies with technology. Mr. Neupert is an audit committee financial expert as a result of his experience, including his experience as CEO and Chairman of drugstore.com. Mr. Neupert previously served as the Board’s lead independent director from July 2019 until June 2023.

Richelle Parham has served as a director of the Company since February 8, 2016. Ms. Parham currently serves as President of Global eCommerce and Business Development for Universal Music Group, a music-based entertainment company, a position she has held since June 2021. Ms. Parham served as a Managing Director of WestRiver Group, which provides integrated capital solutions to the global innovation economy with investments focused on technology, life sciences, energy, and experiential sectors, from October 2019 to May 2021. She is currently a Strategic Advisor at Camden Partners, a private equity firm, where she previously served as a General Partner from October 2016 to October 2019. Prior to Camden Partners, Ms. Parham served as Vice President, Chief Marketing Officer of eBay from November 2010 to March 2015. Ms. Parham was responsible, globally, for eBay brand strategy and brand marketing, to reach 108+ million active eBay users, Internet marketing and for customer relationship management. Prior to joining eBay, Ms. Parham served as head of Global Marketing Innovation and Initiatives and head of Global Marketing Services at Visa, Inc. from 2008 to 2010. Ms. Parham founded and serves as Executive Chairman of the Board of Directors for Shyn, an oral care product company since January 2018. Her experience also includes 13 years at Digitas, Inc., a leading marketing agency, where she held a variety of senior leadership roles, including senior vice president and general manager of the agency’s Chicago office. Ms. Parham has served as a Director of Best Buy Co., Inc. and e.l.f. Beauty, Inc. since March 16, 2018. She served on the board of directors for Scripps Network Interactive Inc. from 2012 until March 2018, when Scripps Network was acquired by Discovery Communications. Ms. Parham holds double Bachelor of Science degrees in business administration and design arts from Drexel University. She became a member of the Drexel University board of trustees in 2014.

Paul B. Rothman has served as a director of the Company and member of the Quality and Compliance Committee since June 6, 2023. Dr. Rothman, a rheumatologist and molecular immunologist, was previously the Dean of the Medical Faculty for Johns Hopkins University School of Medicine and CEO of Johns Hopkins Medicine, during which time he oversaw both the Johns Hopkins Health System and the School of Medicine. Prior to serving at Johns Hopkins, Dr. Rothman held various leadership positions at Columbia University and the University of Iowa. Dr. Rothman holds a Bachelor in Science in biology from the Massachusetts Institute of Technology and an M.D. from Yale University, and is a member of the National Academy of Medicine, the American Academy of Arts and Sciences, the American Association for the Advancement of Sciences, the American Society for Clinical Investigation, and the Association of American Physicians. Dr. Rothman currently serves on the board of directors of Merck and Co. and the King Faisal Specialist Hospital and Research Center in Saudi Arabia.

Kathryn E. Wengel has served as a director of the Company since March 25, 2021. Ms. Wengel has served as the Executive Vice President, Chief Technical Operations & Risk Officer, an Executive Committee member, and an Executive Officer of Johnson & Johnson, a leading healthcare company, since July 2018. Since joining Johnson & Johnson in 1988, Ms. Wengel has served in various positions of increasing responsibility across the enterprise both in the United States and various locations globally, including as the Worldwide Vice President, Chief Global Supply Chain Officer from March 2014 until July 2018, and as the company’s first Chief Quality Officer from April 2010 until March 2014. Ms. Wengel also serves as the Chair of the Board of Directors at the National Association of Manufacturers in the U.S. and as a member of the Board of GS1 Global, a nonprofit that develops and maintains global supply chain standards. Ms. Wengel holds a BSE degree in civil engineering and operations research from Princeton University.